Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies

Progress in Drug Research

Volumn 46, Issue , 1996, Pages 169-181

  Margaglione, M ^a   Grandone, E ^a   Mancini, E P ^a   Di Minno, G ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTILIPEMIC AGENT; FIBRINOGEN; INTERLEUKIN 6; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE C; TICLOPIDINE;

AGE; ATHEROSCLEROSIS; DIABETES MELLITUS; DIET; EXERCISE; HUMAN; LIPID METABOLISM; LIVER; MENOPAUSE; MONOCYTE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; THROMBOSIS;

EID: 0030008761     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0348-8996-4_4     Document Type: Review

References (89)

1. Meade T.W., Chakrabarti R., Haines A.P. et al.: Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1, 1050-1054 (1980).
2. Wilhelmsen K., Svardsudd K., Korsan-B engsten K., Larson B., Welin L.,Tibblin G.: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311, 501-505 (1984).
3. Kannel W.B., Wolf P.A., Castelli W.P., D'Agostino R.B.: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 255: 1183-1186 (1987).
4. Balleisen L., Bailey J., Epping P.H., Shulte H., van de Loo J.: Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using and menopause. Thromb Haemost 54, 475-479 (1985).
5. Stone M.C.,Thorpe J.M.: Plasma fibrinogen as a major coronary risk factor. J R Coll Gen Pract 35, 565-569 (1985).
6. Meade T.W., Brozovic M., Chakrabarti R.R. et al.: Haemostatic function and ischemie heart disease: Principal results of the Northwick Park Heart Study. Lancet 2, 533-537 (1986).
7. Welin L., Svardsudd K., Wilhelmsen L., Larsson B., Tibblin G.: Analysis of risk factors of stroke in a cohort of men born in 1913, N Engl J Med 317, 521-526 (1987).
8. Lee A.J., Smith W.C.S., Lowe G.D.O.,Tunstall-Pedoe H.: Plasma fibrinogen and coronary risk factors: the Scottish heart health study. J Clin Epidem 43,913-919 (1990).
9. Packham M.A., Mustard J.F.:The role of platelets in the development and complications of atherosclerosis. Semin Haematol 23, 8-26 (1986).
10. Lowe G.D.O.: Blood rheology in arterial disease. Clin Sci 71, 137-146 (1986).
11. Leonard E.F.: Rheology in thrombosis, in: Colman R.W., Hirsh J., Marder V.J., Salzman E.W. (Eds.): Hemostasis and thrombosis: basic principles and clinical practice. 2nd ed. Philadelphia: Lippincot 1987, 1111-1122.
12. Smith E.B., Staples E.M., Dietz H.S., Smith R.H.: Role of endothelium in sequestration of lipoprotein and fibrinogen in aortic lesions, thrombi and graft pseudointimas. Lancet 2, 812-816 (1979).
13. Levesque J.P., Hatzfeld A., Hatzfeld J.: Fibrinogen mitogenic effect on hemopoietic cell lines: control via receptor modulation. Proc. Natl. Acad. Sci. USA 83, 6494-7 (1986).
14. Di Minno G., Mancini M.: Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 10, 1-7 (1990).
15. York J.L., Benjamin W.: Quantitative studies on the relationship of fibrinogen and "fibrin" in intima and atherosclerotic plaque. Throm Res 18, 717-724 (1980).
16. Smith E.B.: Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 15, 355-370 (1986).
17. Meade T.W., Imeson J., Stirling Y.: Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet ii, 986-989 (1987).
18. Haust M.D., Wyllie J.C., Moke R.H.: Electron microscopy of fibrin in human atherosclerotic lesions. Exp Mol Pathol 4, 205-216 (1965).
19. Kao V.C.Y., Wissler R.W.: A study of the immuochemical localization of serum lipoproteins and other plasma proteins in human atherosclerotic lesions. Exp Mol Pathol 4, 465-479 (1965).
20. Francis C. W., Markham R.E. Jr., Marder V.J.: Demonstration of in situ fibrin degradation in pathologic thrombi. Blood 63, 1216-1224 (1984).
21. Henschen A., McDonagh J.: Fibrinogen, fibrin and factor XIII. In: Blood Coagulation. Zwaal RFA, Hemker HC (eds.). Elsevier, Amsterdam 1986, pp. 171-241.
22. Hoeprich P.D., Doolittle R.F.: Dimeric half-momlecules of human fibrinogen are joinedthrough disulphide bonds in an antiparallel orientation. Biochemstry 22, 2049-55 (1983).
23. Marino M.W., Fuller G.M., Elder F.F.B.: Chromosomal localisation of human and rat alpha, beta and gamma fibrinogen genes by in situ hybridation. Cytogenet Cell Genet. 42, 36-41 (1986).
24. Buetow K.H., Shiang R., Nakamura Y. et al.: A multipoint genetic map and new RFPLsfor human chromosome 4. Cytogenet. Cell Genet. 51, 973 (1989).
25. Yu S-, Sher B., Kudryk B., Redman C.M.: Intracellular assembly of human fibrinogen. J Biol Chem 258, 13407-13410 (1983).
26. Yu S., Sher B., Kudryk B., Redman C.M.: Intracellular assembly of human fibrinogen. J Biol Chem 259. 10574-10581 (1984).
27. Roy S., Mukhopadhyay G., Redman C.: Regulation of fibrinogen assembly. J. Biol. Chem 265, 6389-6393 (1990).
28. Roy S., Overton O., Redman C.: Overexpression of any fibrinogen chain by Hep G2 cells specifically elevates the expression of the other two chains. J. Biol. Chem. 269, 691-695 (1994).
29. Hamsten A., Iselius L., De Faire U., Blomback M.: Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet i, 988-990 (1987).
30. Berg K., Kierulf P.: DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentrations. Clin. Genet. 36, 229-235 (1989).
31. Humphries S.E., Cook M., Dubowitz M., Stirling Y., Meade T.W.: Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet i, 1452-1455 (1987).
32. Margaglione M., Grandone E., Di Minno G.: Genetic modulation of plasma fibrinogen concentrations. Implications for thrombotic complication of atherosclerosis. J. Thrombos.Thrombolys. 1995 (in press).
33. Meade T.W., Chakrabarti, Haines A.P., North W.R.S., Stirling Y.: Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Lancet i, 153-156 (1979).
34. Balleisen L., Bailey J., Epping P.H. et al.: Epidemiology study on Factor VII, Factor VIII and Fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body weight, smoking, alchool, pill using and menopause.Thromb. Haemstas. 54, 475-479 (1985).
35. Ritchie D.G., Levy B.A., Adams M.A., Fuller G.M.: Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: An indirect feedback pathway. Proc Natl Acad Sci 79, 1530-1534 (1982).
36. Ritchie D.G., Fuller G.M.: Hepatocyte-stimulating factor: a monocyte derived acutephase regulatory protein. Ann New York Acad Sci, 490-500 (1983).
37. Hermann F. Martelsmann R.: Polypeptides controlling hematopoietic cell development andactivation. Blut 58, 117 (1989).
38. Baumann H., Richards C., Gauldie J.: Interaction among hepatocyte-stimulating factors, interleukin 1 and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (Hep G2) cells. J. Immunol. 139, 4122-8 (1987).
39. Evans E., Courtois G.M., Kilian P., Fuller G.M., Crabtree G.R.: Induction of fibrinogen and a subset of acute phase response genes involves a novel monokine which is mimicked by phorbol esters. J Biol Chem 262, 10850-854 (1987).
40. 2 HPGF). EMBO J. 6, 1219 (1987).
41. Le J., Vilcek J.: Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 61, 588-602 (1989).
42. Heinrich P.C., Castell J.V., Andus T.: Interleukin 6 and the acute phase response. Biochem J 265, 621-636 (1990).
43. Ramadori G., Van Damme J., Reter H., Meyer-Zum-Buschenfelte H.M.: Interleukin 6, the third mediator of acute phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1β and tumor necrosis factor. Eur. J. Immunol. 18, 1259-64 (1988).
44. Schindler R., Mancilla J., Enders S. et al.: Correlations and interactions in the production of inteleukin 6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 supresses IL-1 and TNF. Blood 75, 40 (1990).
45. Dinarello C.A.: Interleukin-1 and interleukin-1 antagonism. Blood 77, 1627-1652 (1991).
46. Hassan J., Chelucci C, Peschle C., Sorrentino V: Transforming growth factor β (TGFβ) inhibits expression of fibrinogen and factor VII in a hepatoma cell line. Thromb. Haemostas. 67, 478-483 (1992).
47. Poli V, Cortese R.: Interleukin 6 induces a liver-specific nuclear protein that binds to the promoter of acute-phase genes. Proc Natl Acad Sci 86, 8202-8206 (1989).
48. Poli V, Mancini F.P., Cortese R.: IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBO. Cell 63, 643-653 (1990).
49. Burr M.L., Fehiky A.M., Gilbert J.F., Rogers S., Holliday R.M., Sweetnam P.M., El wood P.C., Deadman N.M.: Effects of changes in fat, fish and fibreintakes on death and myocardial infarction: diet and reinfarction trial (DART). Lancet 2, 757-761 (1989)
50. Endres S., Ghorbani R., Kelley V.E., Georgilis K., Lonnemann G., van der Meer J., Cannon J.G., Rogers T.S., Klempner, Weber P., Schaefer E.J., Wolff S.M., Dinarello C.A.: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. New Engl J Med 320, 265-271 (1989).
51. Sperling R.J., Robin J.L., Kylander K. A., Lee T.K., Lewis R. A., Austen K.F.: The effects of n-3 polyunsaturated fatty acids on the generation of platelet activating factor-acether by human monocytes. J Immunol 139, 4186-4191 (1987).
52. Takayashi R., Manku M.S., Horrobin D.F.: Impaired platelet aggregation and thromboxane generation in essential fatty-acid deficient rats. J Nutr 117, 1520-1526 (1987).
53. Hostmark A.T., Bjerkedal T., Kierulf P., Flaten H., Ulshagen K.: Fish oil and plasma fibrinogen. Br Med J 297, 180-181 (1988).
54. Radack K., Deck C., Huster G.: Dietary supplementation with low-dose fish oils lowers fibrinogen levels: a randomized, double-blind controlled study. Ann Intern Med 111, 757-758 (1989).
55. Schmidt E.B., Varming K., Ernst E., Dyerberg J.: Dose-response studies on the effect of n-3 polyunsaturated fatty acids on lipids and haemostasis. Thromb Haemost 63, 1-5 (1990).
56. Venter C.S., Vorster H.H., van der Nest D.G.: Comparison between physiological effects of konjac-glucomannan and propionate in baboons fed "western" diets. J Nutr 120, 1046-1053 (1990).
57. Oosthuizen W.,Vorster H.H., Jerling J.C. et al.: Both fish and olive oil lowered plasma fibrinogen in women with high baseline fibrinogen levels. Thrombos. Haemostas. 72, 557-62 (1994).
58. Schmidt E.B., Pedersen J.O., Varming K. et al.: n-3 fatty acids and leukocyte chemiotaxis. Effects in hyperlipidemia and dose-response studies in health men. Arterioscleros. Thrombos. 11, 429-435 (1991).
59. Goodnight S.H.: Fish oil: effects on atherogenesis and thrombosis. Curr Op Lipidol 1, 334-340(1990).
60. Aukland A., Hurlow R.A., George A.J., Stuart J.: Platelet inhibition with ticlopidine in atherosclerotic intermittent claudication. J. Clin. Pathol. 35, 740-743 (1982).
61. Palareti G., Poggi M.,Teoricelli P. et al.: Longterm effect of ticlopidine on fibrinogen and hemorheology in patients with peripheral arterial disease. Thromb. Res. 52, 621-629 (1988).
62. Balsano F., Coccheri S., Libretti A., Nenci G.G., Catalano M.M., Fortunato G., Grasselli S., Violi F., Hellemans H., Vanhove P.H.: Ticlopidine in the treatment of intermittent claudication: a 21 month double-blind trial. J Lab Clin Med 114, 84-91 (1989).
63. Balsano F., Rizzon P., Violi F. and the STAI group: Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicentre clinical trial. Circulation 82, 17-26 (1990).
64. Janzon L., Bergqvist D., Boberg J., Boberg M., Eriksson J., Lindgarde F., Persson G.: Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine: Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Int Med 227, 301-308 (1990).
65. McTavish D., Faulds D., Goa K.: Ticlopidine: an updated review of its pharmacology, and therapeutic use in platelet-dependent disorders. Drugs 40, 238-259 (1990).
66. Jarret P.E.M., Moreland M., Browse N.L.:The effect of oxpentifylline on fibrinolytic activity and plasma fibrinogen levels. Curr Med Res Opinion 4. 1492-1495 (1977).
67. Takamatsu S., Sato K.,Takamatsu M., Sakuts S., Mizuno S.: A two year follow up study on blood constituents in aged arteriosclerotic patients trteated with pentoxifylline. Proceedings of the 28th Int Congress of Physiological Sciences, Tübingen, West Germany, 1980.
68. Muggeo M., Calabro A., Businaro V., Patussi L., Volpe A., Signorini G.P., Crepaldi G.: Blood clotting, fibrinolytic and haemorheological parameters in ischaemic vascular disease: the effects of pentoxifylline in the treatment of acute vascular disease. Pharmacotherapeutica 3 (suppl 1), 74-90 (1983).
69. Di Perri T., Carandente O., Vittorio O., Guerrini N., Messa G.L.: Studies on the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease. Angiology 35, 427-435 (1984).
70. Ott E., Fazekas F., Lechner H.: Haemorheological effects of pentoxifylline in disturbed blood flow behaviour in patients with cerebrovascular disease. Neurology 22 (suppl 1), 105-107 (1983).
71. Zacharski L.R., Henderson W.G., Rickles F.R. et al.: Rationale and experimental design for the VA Cooperative Study of RA 233 in the treatment of cancer. Am. J. Clin. Oncol. 5, 593-609 (1982).
72. Zacharski L.R., Moritz T.E., Baczek L.A. et al.: Effect of RA-233 (Mopidamole) on survival in carcinoma of the lung and colon. Final report of the VA Cooperative Study 188. J. Natl. Cancer Inst. 80, 90-97 (1988).
73. Watson S.P., McConnel R.T., Lapetina E.G.: The formation of inositol phosphates in human platelets by thrombin is inhibited by prostacyclin. J. Biol. Chem. 259, 13199-13203 (1984).
74. Rittenhouse-Simmons S.: Production of diglyceride from phosphatidylinositol in activated human platelets. J Clin Invest 63, 580-587 (1979).
75. Rall T.W.: Evolution of the mechanisms of action of methylxanthines: from calcium mobilizers to antagonists of adenosine receptors. Pharmacologist. 24, 277-287 (1982).
76. Sirtori C.R., Colli S.: Influences of lipid-modifying agents on hemostasis. Cardiovasc. Drug Ther. 7, 817-823 (1993).
77. Hertz R., Bar-Tana J., Sujatta M. et al.: The induction of liver peroxisomal proliferation by β,β-methyl-substituted hexadecanedioic acid (MEDICA 16). Biochem. Pharmacol. 37, 3571-77 (1988).
78. Issemann I., Green S.: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-649 (1990).
79. Ciuffetti G., Orecchini G., Siepi D. et al.: Hemorheological activity of gemfibrozil in primary hyperlipidemias. In: Paoletti R. et al. (eds.): Drugs affecting lipid metabolism. Berlin: Springer-Verlag, 1987, 372-375.
80. Niort G., Bukgarelli A., Cassader ML, Pagano G.: Effect of short term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 71, 113-119 (1988).
81. Andersen P., Smith P., Seljeflot I., Brataker S., Arnesen H.: Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 63, 174-177 (1990).
82. Mori J., Wada H., Nagano Y. et al.: Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis. Effect of probucol on coagulation. Thromb. Haemostas. 67, 140-143 (1989).
83. Franceschini G., Chiesa G., Sirtori C.R.: Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients. Eur. J. Clin. Invest. 21, 384-388 (1991).
84. Parthasarathy S., Young S.G., Witzum J.L. et al.: Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 77, 641-644 (1986).
85. Di Minno G., Davi G., Margaglione M. et al.: Abnormally high thromboxane byosinthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J. Clin. Invest. 92, 1400-1406 (1993).
86. Stampfer M.J., Colditz G.A., Willet W.C., Speizer F.E., Hennekens C: A prospective study of moderate alcohol consuption and the risk of coronary disease and stroke in women. N Engl J Med 319, 267-273 (1988).
87. Di Minno G., Ames P.R.J.: Developing relationships. Intracerebral bleeding, cardiovascular protection and haemostaic variables in moderate alcohol consumers. Thromb. Haemorrh. Disorders 5, 1-4 (1992).
88. Bagasra O., Howeedy A., Kajdacsy-Balla A.: Macrophage function in chronic experimental alcoholism. Modulation of surface receptors and phagocytosis. Immunology 65, 405-409 (1988).
89. Stuart J., George A.J., Davies A.J. et al.: Haematological stress syndrome in atherosclerosis. J. Clin. Pathol. 34, 464-467 (1981).